treatment effect during infection in the same model. Parallel in vitro growth experiments were 23 conducted as proof-of-concept. Our data demonstrate that the activity of commonly used 24 antibiotics Ceftriaxone and Gentamicin correlated with pre-treatment bacterial growth rate; both 25 drugs performing better during rapid growth than during slow growth. Conversely, Ciprofloxacin 26 was less sensitive to bacterial growth rate, both in a homogenous in vitro bacterial population and 27 in a more heterogeneous in vivo bacterial population. The method serves as a platform to test any 28 antibiotic's dependency upon active in situ bacterial growth. Improved insight into this 29 relationship in vivo could ultimately prove helpful in evaluating future antibacterial strategies. 30 31 Importance 32 Most antibiotics in clinical use exert their effect predominantly on rapidly growing bacterial cells, 33 yet there is a lack of insight into bacterial growth dynamics taking place during infection in vivo. 34 We have applied inexpensive and easily accessible methods for extraction of in situ bacterial 35 growth rate from bacterial chromosome replication during experimental murine infection. This 36 approach not only allows for a better understanding of bacterial growth dynamics taking place 37 during the course of infection, but also serves as a platform to test the activity of different 38 antibiotics as a function of pre-treatment in situ growth rate. The method has the advantage that 39 bacterial growth rate can be probed from a single biological sample, with the potential for 40 extension into clinical use in pre-treatment infected biological specimens. A better understanding 41 of commonly used antibiotics' level of dependency upon bacterial growth, combined with Introduction 46 Studies of antibacterial activity are largely based on laboratory models, where balanced bacterial 47 populations propagate rapidly in well-defined batch cultures with a finite quantity of life-48 sustaining nutrients. These in vitro models fail to mirror the true growth dynamics of bacterial 49 pathogens taking place during infection in vivo, where growth in a bacterial population appears to 50 be both slower and less homogeneous (1-3). The dependency upon active bacterial growth for 51 most antibiotics to exert their effect is acknowledged and has been examined by other 52 investigators, both in vitro and in vivo (4-11). However, these studies were largely based on 53 bacterial count kinetics as a direct measure of bacterial growth rate. This measure could be 54 misleading during infection in vivo, where the net change in bacterial count is a function not only 55 of growth, but also of elimination of bacterial cells by the host immune system; a factor not taken 56 into account in the bacterial count kinetics method. Moreover, the method fails to report on any 57 growth heterogeneity within the bacterial population. Hence, there is a need for refined means to 58 measure bacterial growth that can extend into clinical use. To date, no gold standard method for 59 measuring in vivo bacterial growth rate exists. In recent years, it has been demonstrated possible 60 to extract direct measures of in vivo bacterial growth rate by analysing differential genome 61 coverage in whole-genome sequencing data (12, 13) . This method circumvents the limitation of a 62 non-quantifiable bacterial elimination factor, as it reports directly on the bacteria's physiological 63 state. Nonetheless, it reports merely on the population mean growth rate. 64 Most bacterial chromosomes are circular with a single origin of replication (oriC), from where 65 chromosome replication is initiated and carried out bidirectionally toward a single, opposite 66 located terminus (terC) during bacterial growth (14, 15) . In Escherichia coli it is acknowledged, 67 from decades of in vitro studies, that bacterial growth rate is a function of growth conditions and 68 4 is precisely coordinated with genome replication (16) (17) (18) . When growth conditions are favourable, 69 overlapping rounds of synchronously initiated bidirectional chromosome replication occur, 70 allowing for the presence of more than two oriCs (number of oriC copies = 2 n (n = 2, 3, 4)) in 71 rapidly growing cells (17, 19) . In contrast, when growth conditions are disadvantageous, no or 72 merely one round of chromosome replication occur, allowing for the presence of only one or 73 maximum two oriCs (number of oriC copies = 2 n (n = 0, 1)) in non-or slowly growing cells (19) . 74 Hence, the copy number ratio of oriC to terC (i.e. ori:ter) reflects the bacterial population growth 75 rate: during rapid growth larger fractions of cells undergo one or more round(s) of chromosome 76 replication (i.e. population mean ori:ter ≥ 2) and during slow or no growth only few cells will 77 undergo chromosome replication (i.e. population mean ori:ter ~ 1) (20). By the use of two 78 complementary methods for measuring ori:ter: quantitative PCR (qPCR) and fluorescence 79 microscopy, we have been able to probe in situ growth rates of fluorescently labelled E. coli 80 ATCC® 25922™ both on a population average (by qPCR) and on a single-cell (by fluorescence 81 microscopy) level during wide-spread infection in the mouse peritonitis model (3). We 82 demonstrated correlation between ori:ter and bacterial cell size at all growth rates and the ability 83 of ori:ter to predict the development in net bacterial population size. Moreover, in this recent 84 observation of growth dynamics during host infection we found that growth rates were largely 85 heterogeneous within the bacterial populations propagating both in the peritoneum and in the 86 blood, respectively, throughout the length of infection (3). This finding is in consistency with 87 previous reports of Staphylococcus aureus growth rate heterogeneity in cystic fibrosis sputum, as 88 measured by isotope tracing (1). These observations underscore the need for refined and easily 89 accessible methods to measure the in situ bacterial growth rate taking place during various types 90 of infection and its causal relationship with the outcome of antibacterial treatment. 91 5 Here, we extended the approach of using chromosome replication as readout for in vivo bacterial 92 growth rate in the mouse peritonitis model to explore its potential in predicting antibacterial 93 treatment effect. For comparison, we chose a representative drug from each of three classes of 94 commonly used bactericidal antibiotics with different cellular targets: Ceftriaxone (CRO; a β-95 lactam), Ciprofloxacin (CIP; a Fluoroquinolone) and Gentamicin (GEN; an Aminoglycoside) (21). We 96 hypothesized that the drugs tested would perform better when given during rapid, than during 97 slow bacterial growth. given as a single-dose during rapid or slow bacterial growth, respectively. Antibiotic 117 concentrations were standardised and defined from previous studies, and corresponded to serum 118 concentrations observed in humans on standard dosing regimens: Ceftriaxone 30 mg/l; 119 Ciprofloxacin 1 mg/l; Gentamicin 10 mg/l (23-28). Sampling was performed after two hours of 120 antibiotic exposure. There was temporal difference in pre-treatment bacterial load at the time 121 points chosen for rapid and slow bacterial growth treatment induction, respectively. Hence, 122 antibiotic activity was measured as the difference in pre-and post-treatment bacterial count, 123 relative to the pre-treatment bacterial count (i.e. relative ∆log 10 CFU/ml), for comparison. 124 We tested the wild-type bacterial strain (ATCC 25922) in parallel to the genetically modified 125 derivative of the strain, with chromosomally incorporated fluorescent oriC and terC labels (ALO 126 4783), to ensure the absence of growth retardation due to transgene insertion. As no growth 127 differences were observed ( Fig. 1a ), in vitro data from both versions of the strain were pooled for 128 analysis. In regard to the Gentamicin treatment regimen, however, only wild-type ATCC 25922 was 129 applied, as the Gentamicin MIC was increased by the presence of the non-removable Kanamycin 130 cassette encoding Kanamycin phosphotransferase, used as clonal selection marker, in ALO 4783 131 7 demonstrated that E. coli population growth in LB is close to balanced and dominated by large 137 cells growing with overlapping rounds of chromosome replication (3). This is exemplified in Figure   138 2, image A, illustrating a large bacterial cell with multiple oriCs. As a consequence of rapid bacterial 139 growth there was subsequent increase in population size ( Fig. 1a -b ). Between 4 and 6 hours of 140 incubation growth was starting to slow down, illustrated by a reduction of ori:ter at 6 hours of 141 incubation and following minimal increase in net population size ( Fig. 1a -b ). 142 When introduced into a batch culture of rapidly growing cells, all antibiotics resulted in significant 143 bacterial count reduction, compared to controls (CRO and CIP, P < 0.001; GEN, P < 0.01) ( Fig. 1c ). 144 Correspondingly, single-cell microscopic analysis of pooled live bacterial cells from treatment 145 batch cultures revealed that the majority of the cells we were able to isolate after exposure to 146 either Ceftriaxone or Ciprofloxacin were affected by the treatment, when introduced during rapid 147 bacterial growth (Fig. 2 , image C and D, respectively). These bacterial populations were 148 represented predominantly by spherical and filamentous cells (Ceftriaxone), or elongated cells 149 (Ciprofloxacin); all with multiple fluorescent foci, representing direct or indirect chromosome 150 replication disturbance. Unfortunately, we were unable to accurately quantify the population 151 distribution of oriC and terC, respectively, due to multiple, overlapping fluorescent foci in these 152 treatment groups. The morphological changes in the Ceftriaxone exposed bacterial populations 153 suggest that Ceftriaxone exerted its bactericidal effect through cell-wall inhibition predominantly 154 by binding to Penicillin-binding proteins (PBPs) 2 and 3, in accordance with previous studies (30). 155 We underscore that the microscopy data from bacterial cultures treated with antibiotics during 156 rapid growth (Fig. 2 , image C -E) are subject to uncertainty given that only few live bacterial cells 157 (n < 500) were isolated due to the efficient bacterial killing (Fig. 1c) . Nevertheless, ori:ter 158 extracted from qPCR complemented the above described microscopy findings regarding 159 8 chromosome replication: high ori:ter ratios were observed where photomicrographs were 160 dominated by large cells with multiple oriCs, and low ori:ter ratios where photomicrographs were 161 dominated by small cells with few oriCs, in both treatment and control groups ( Fig. 1e and Fig. 2,   162 images A -E). Only Ciprofloxacin administered during rapid growth entailed significantly higher 163 ori:ter, compared to post-treatment controls (P < 0.01) ( Fig. 1e ). As to Ceftriaxone and Gentamicin 164 treatment administered during rapid bacterial growth, both induced a decrease in ori:ter toward ~ 165 1, similar to that of the control group (Fig. 1e ). For Gentamicin treated bacterial cells, microscopic 166 visualisation of oriC and terC was not possible as only the wild-type ATCC 25922 was applied. The 167 size and morphology of the cells did, however, not appear to differ from that of the respective 168 control population (Fig. 2 , images E and B, respectively).
170

Antibiotics administered during slow bacterial growth in vitro 171
At 8 hours of incubation minimal bacterial growth rates (expressed as mean (SD) ori:ter = 1.01 172 (0.07)) were reached due to nutrient starvation ( Fig. 1b ). At this stage, it has been demonstrated 173 that the bacterial population is dominated by small bacterial cells without ongoing chromosome 174 replication, i.e. complete or near complete cessation of growth (3). This is exemplified in Figure 2 , 175 image F, illustrating small bacterial cells with predominantly one oriC/cell. Consequently, there 176 was no significant subsequent net population size increase, and all parameters remained largely 177 unchanged by 10 hours of incubation ( Fig. 1a -b and Fig. 2 , image G). When identical antibiotic 178 regimens as those applied during rapid bacterial growth were introduced into this population of 179 slowly / non-growing bacterial cells, only Ciprofloxacin caused significant bacterial count reduction 180 (P < 0.01); albeit considerably less than when administered during rapid growth, where a near 181 total clearance of cells was observed ( Fig. 1c -d ). Ceftriaxone and Gentamicin treatment effect 182 9 was absent ( Fig. 1d ). Correspondingly, photomicrographs were dominated by cells largely 183 unaffected by all three antibiotics, when compared to post-treatment controls (Fig. 2 , images G -184 J), and no significant change in ori:ter was observed in any treatment group, compared to post-185 treatment controls (Fig. 1f) . The Ciprofloxacin-induced increase in ori:ter observed during rapid 186 bacterial growth treatment ( Fig. 1e and Fig. 2 , image D) was absent when Ciprofloxacin was added 187 to a population of cells largely without ongoing chromosome replication (mean population ori:ter 188 ~ 1) ( Fig. 1f and Fig. 2 , image I). 196 were lost when identical treatment regimens were induced during slow bacterial growth. 197 Ciprofloxacin, however, was less sensitive to active bacterial growth, as a significant reduction in 198 bacterial load was observed upon administration during both rapid and slow growth. During propagation in this infection model, bacterial growth was overall slower than in vitro, yet 206 never came to a complete cessation (i.e. ori:ter remained > 1 at all times) during the length of the 207 experiment ( Fig. 3a) . All antibiotics were administered as a single-dose subcutaneously (s.c.) 208 during rapid or slow bacterial growth, respectively, in the following concentrations: Ceftriaxone 5 209 mg, Ciprofloxacin 0.4 mg and Gentamicin 1 mg per mouse, respectively. Antibiotic concentrations 210 were defined from previous studies (23-28) and all were > minimum 10×MIC (Table 1) The bacterial populations reached maximal in situ growth rates (expressed as mean (SD) ori:ter PLF 218 = 2.54 (0.30); ori:ter blood = 2.37 (0.46)) at 2 hours of infection ( Fig. 3a) . At this stage of infection, 219 it has been demonstrated that bacterial population growth is heterogeneous (i.e. the population is 220 made up of bacterial cells of various sizes and DNA content) (3). Figure 4 , image A, illustrates a 221 representative large cell with multiple oriCs, isolated from the PLF. As a consequence of average 222 rapid growth rates, there was subsequent increase in net bacterial population size in all biological 223 specimens (Fig. 3a) . After 2 hours of infection there was a gradual decrease in ori:ter, resulting in 224 overall net population stagnation between 8 and 10 hours of infection (Fig. 3a) . 225 When administered during rapid bacterial growth, all antibiotics (CRO, CIP and GEN) caused 226 significant bacterial count reduction at all anatomical sites examined (PLF, blood, spleen and 227 kidneys, P < 0.01), including a total elimination in blood and kidneys, compared to respective 228 11 controls (Fig. 3b) . The anatomical site-specific differences in antibiotic activity observed (e.g. 229 between the blood and PLF) ( Fig. 3b ) cannot be explained by differences in site-specific in situ pre-230 treatment ori:ter, as these were not significantly different (P > 0.5) (Fig. 3a) . Rather, these 231 differences are conceivably attributable to other pharmacodynamic and / or host immune 232 parameters. 233 We were able to isolate only few live bacterial cells for fluorescence microscopy from infected 234 body fluids in pre-and post-treatment control groups during rapid bacterial growth (Fig. 4 , images 235 A -B ) due to low bacterial counts during early hours of infection ( Fig. 3a) . Given the substantial or 236 total clearance of bacteria from the PLF and blood following antibiotic exposure during rapid 237 bacterial growth, we were unable to isolate live bacterial cells from these treatment groups (Fig.   238 4). However, the overall ori:ter developments in these treatment groups were similar to those 239 observed during rapid growth in vitro: Ciprofloxacin treatment induced significantly higher ori:ter 240 ratios compared to post-treatment controls (P < 0.05), and ori:ter developments in Ceftriaxone 241 and Gentamicin treatment groups were similar to those of the post-treatment controls (i.e. 242 reduction toward ~ 1); with Ceftriaxone being most efficient (P < 0.05) (Fig. 3d ).
244
Antibiotics administered during slow bacterial growth in vivo 245
Minimal bacterial growth rates (expressed as mean (SD) ori:ter PLF = 1.53 (0.2) and ori:ter blood = 246 1.57 (0.29)) were observed starting from 8 hours of infection (Fig. 3a) . Marginally lower ori:ter 247 levels were observed in bacteria isolated from both PLF and blood at 10 hours of infection (mean 248 (SD) PLF = 1.48 (0.17) and ori:ter blood = 1.34 (0.24)) ( Fig. 3a) . However, these differences were 249 not statistically significant (P > 0.5), and, at this time the criteria for euthanasia were met for 250 12 control animals. Hence, 8 hours of infection was chosen as the time point for slow bacterial 251 growth treatment induction. 252 When administered during slow bacterial growth, only Ciprofloxacin treatment caused significant 253 bacterial count reductions at all anatomical sites (PLF, blood, spleen and kidneys, P < 0.01 (Fig.   254 3c). The activity of Gentamicin was overall reduced, and Ceftriaxone activity was substantially 255 reduced at all anatomical sites when antibiotics were administered during slow bacterial growth, 256 compared to during rapid bacterial growth (Fig. 3b -c) . 257 Photomicrographs of live bacterial cells exposed to antibiotics during slow bacterial growth 258 indicated that the drugs exerted their effect similar to that in vitro: Ceftriaxone inhibiting cell wall 259 synthesis predominantly via PBP 2 (demonstrated by the presence of spherical cells) and PBP 3 260 (demonstrated by the presence of filamentous cells) (30) (Fig. 4 , image E), and Ciprofloxacin 261 interrupting natural bacterial growth by inducing cell enlargement with multiple fluorescent foci 262 due to interference with ongoing chromosome replication (Fig. 4 , image F) (31). Due to multiple, 263 overlapping fluorescent foci in these treatment groups, we were unable to accurately quantify the 264 population distribution of oriC and terC, respectively. For Gentamicin treated bacterial cells, 265 microscopic visualisation of oriC and terC was not possible as the wild-type ATCC 25922 was 266 applied. The size and morphology of the bacterial cells did, however, not appear to differ from 267 that of the respective control population, as observed after antibiotic administration during slow 268 bacterial growth (Fig. 4 , Images D and G). We emphasize the uncertainty in these microscopy data 269 ( Fig. 4 , Images H -J), as only few live bacteria (n < 500) were isolated due to antibiotic induced 270 bacterial killing (Fig. 3c ). 271 The bacterial populations (both in PLF and blood) exposed to antibiotics during late stage of 272 infection (i.e. at 8 hours of infection, Fig. 3a ) differed from that observed after prolonged 273 13 propagation in vitro (i.e. at 8 hours of incubation; Fig 1b) in that there was no complete cessation 274 of growth in the former. Here, fractions of the population were still undergoing chromosome 275 replication (as expressed by the mean ori:ter > 1). Hence, the effect of Ciprofloxacin on ori:ter was 276 apparent also upon treatment during slow bacterial growth (Fig. 3e ). In this study, we determined the activity of three commonly used bactericidal antibiotics with 291 different antibacterial targets as a function of in situ bacterial growth rate, expressed as 292 differential genome origin and terminus copy number quantification (ori:ter) by qPCR. We 293 demonstrated that overall activities of both Ceftriaxone and Gentamicin were substantially lower 294 when administered during slow bacterial growth, than during rapid bacterial growth in vivo. 295 Contrarily, Ciprofloxacin was less sensitive to bacterial growth rate, as the overall activity 296 14 remained largely unchanged when going from rapid to slow bacterial growth rate treatment 297 induction in vivo. The findings of Ciprofloxacin being less sensitive to bacterial growth rate than β-298 lactams and Aminoglycosides, respectively, has been demonstrated by others, however with the 299 limitation of bacterial growth rate being estimated from net bacterial population kinetics (9, 10). 300 In the parallel in vitro experiments, the difference between rapid and slow bacterial growth rate 301 was more explicit, including complete or near complete cessation of growth as the lower extreme Rather, the Ceftriaxone or Gentamicin induced ori:ter reduction toward ~ 1 is likely the result of 320 preferential elimination of fractions of rapidly growing bacterial cells (i.e. those with ori:ter > 1). 321 Hence, besides allowing for measurement of pre-treatment in situ bacterial growth rate, ori:ter 322 may to some extent, demonstrate antimicrobial mode of action by analysis of post-treatment 323 ori:ter. Fluorescence microscopy can complement these findings by direct single-cell visualisation, 324 as demonstrated, yet is limited by the absence of live bacterial cells after efficient bacterial 325 elimination. 326 The growth rate scenarios observed during bacterial propagation in vitro were not representative 327 of the bacterial growth dynamics taking place during infection in a complex host environment. In 328 the latter, a complete or near complete cessation of bacterial growth was not observed as long as 329 the host was alive and bacterial life-sustaining nutrients presumably not exhausted. Hence, for 330 more meaningful prediction of antibiotic activity in vivo, it is important to be able to test this in 331 relation to the in situ bacterial growths rate taking place during host infection, rather than 332 extrapolating from in vitro studies. ori:ter provides predictive value in informing on the likelihood 333 of antibiotic activity, both during E. coli propagation in vitro and in vivo during host infection. 334 There are, however, limitations to be considered in this study. Maximal bacterial growth rates 335 were observed after few hours of propagation, while minimal growth rates were only observed 336 after prolonged propagation, both in vitro and in vivo. Consequently, the net bacterial population 337 sizes were larger during slow, than during rapid bacterial growth. For meaningful comparison of 338 effect between identical antibacterial treatment regimens applied, we calculated the relative 339 killing effect in both scenarios. We cannot exclude the possibility of an inoculum effect as 340 contributing factor to the lower antibiotic activity observed during slow bacterial growth. This is, 341 however, a phenomenon mainly observed for β-lactams and rather unlikely to have occurred at 342 16 the high antibiotic concentrations that were applied, both in vitro and in vivo (32). Moreover, we 343 were unable to adequately purify bacterial DNA from spleen and kidney tissues. Hence, the 344 difference in spleen and kidney antibiotic treatment effect between the two scenarios in vivo is 345 only assumed to owe to different in situ bacterial growth rate in these tissues. Yet, as the temporal 346 development in net bacterial population size from these tissues followed those of the PLF and 347 blood, we find it likely that bacterial growth rates in the tissues would also be higher during early 348 hours of infection, than after prolonged propagation. 349 We conclude that chromosome replication as a means to measure bacterial growth rate can For in vitro experiments, bacteria were grown in Lysogeny Broth (LB) as previously described (3). 388 Antibiotics were added to each batch culture at either maximal bacterial growth rate (i.e. at 4 389 hours of incubation) or at minimal bacterial growth rate (i.e. at 8 hours of incubation), 390 respectively. Samples for quantification of bacterial count, qPCR analysis and fluorescence 391 microscopy were withdrawn pre-treatment (i.e. at 4 or 8 hours of incubation, respectively) and 392 after two hours of antibiotic exposure (i.e. at 6 or 10 hours of incubation, respectively). All samples 393 were immediately set on ice after withdrawal. Control cultures without antibiotic treatment 394 exposure were included in every experiment. 395 Both treatment studies were performed in duplicate, including both ATCC 25922 wild-type and the 396 genetically modified ALO 4783, in three independent experiments. Both versions of the strain 397 were tested in parallel to ensure the absence of any alterations in growth or antibiotic treatment 398 effect attributable to the transgene insertions. As both growth curves and ori:ter were similar for 399 both versions of the strain, these results were pooled for statistical analyses. 400 Regarding Gentamicin treatment, only the wild-type ATCC 25922 was applied, as the Gentamicin 405 The mouse peritonitis model was carried out as previously described, using outbred female NMRI 406 mice (weight 28 ±2 g; Taconic, Denmark) (3). Animals were kept in cages in groups of three; each 407 cage constituting one experimental unit that would be randomly assigned to treatment (CRO, CIP 408 or GEN) or no treatment (control; CTR). Antibiotics were administered as a single bolus injection 409 subcutaneously (s.c.) at either maximal bacterial growth rate (i.e. at 2 hours of infection) or 410 19 minimal bacterial growth rate (i.e. at 8 hours of infection). Sample collections (peritoneal lavage 411 fluid (PLF), blood, spleen and kidneys) were performed pre-treatment (i.e. at 2 or 8 hours of 412 infection, respectively) in control groups, and after two hours of antibiotic exposure (i.e. at 4 or 10 413 hours of infection, respectively) in both treatment and control groups. Euthanasia and harvesting 414 of biological specimens were carried out as previously described (3) Bacterial count measurements from in vitro and in vivo experiments were performed as previously 434 described (3). Antibacterial activity was measured as the difference between bacterial count pre 435 and post therapy (∆log 10 CFU/ml). For meaningful comparison between identical treatment 436 regimens administered at different growth rates (i.e. different pre-treatment bacterial load), 437 antibacterial activity was illustrated as ∆log 10 CFU/ml relative to the pre-treatment bacterial count 438 (relative ∆log 10 CFU/ml). 
Mouse peritonitis model experiments (in vivo)
